- Home
- ANIX
as of 11-02-2026 3:30pm EST
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 103.9M | IPO Year: | 2013 |
| Target Price: | $9.67 | AVG Volume (30 days): | 203.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | 12.82 |
| 52 Week Low/High: | $2.32 - $5.46 | Next Earning Date: | 09-09-2026 |
| Revenue: | $210,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -13.61 | Index: | N/A |
| Free Cash Flow: | -7188791.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Anixa Biosciences Inc. (ANIX)
Chief Executive Officer
Avg Cost/Share
$3.17
Shares
5,000
Total Value
$15,850.00
Owned After
685,000
SEC Form 4
Director
Avg Cost/Share
$2.98
Shares
8,000
Total Value
$23,840.00
Owned After
1,054,003
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$2.72
Shares
8,000
Total Value
$21,760.00
Owned After
685,000
SEC Form 4
President, COO, & CFO
Avg Cost/Share
$2.84
Shares
5,500
Total Value
$15,620.00
Owned After
50,000
SEC Form 4
Director
Avg Cost/Share
$2.76
Shares
5,000
Total Value
$13,800.00
Owned After
140,572
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$2.78
Shares
7,000
Total Value
$19,460.00
Owned After
685,000
SEC Form 4
Director
Avg Cost/Share
$2.73
Shares
10,000
Total Value
$27,300.00
Owned After
1,054,003
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$2.76
Shares
8,000
Total Value
$22,050.00
Owned After
685,000
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KUMAR AMIT | ANIX | Chief Executive Officer | Oct 30, 2026 | Buy | $3.17 | 5,000 | $15,850.00 | 685,000 | |
| Titterton Lewis H jr | ANIX | Director | Oct 23, 2026 | Buy | $2.98 | 8,000 | $23,840.00 | 1,054,003 | |
| KUMAR AMIT | ANIX | Chief Executive Officer | Oct 22, 2026 | Buy | $2.72 | 8,000 | $21,760.00 | 685,000 | |
| Catelani Michael | ANIX | President, COO, & CFO | Sep 30, 2026 | Buy | $2.84 | 5,500 | $15,620.00 | 50,000 | |
| Baskies Arnold M | ANIX | Director | Sep 24, 2026 | Buy | $2.76 | 5,000 | $13,800.00 | 140,572 | |
| KUMAR AMIT | ANIX | Chief Executive Officer | Sep 24, 2026 | Buy | $2.78 | 7,000 | $19,460.00 | 685,000 | |
| Titterton Lewis H jr | ANIX | Director | Sep 10, 2026 | Buy | $2.73 | 10,000 | $27,300.00 | 1,054,003 | |
| KUMAR AMIT | ANIX | Chief Executive Officer | Sep 10, 2026 | Buy | $2.76 | 8,000 | $22,050.00 | 685,000 |
Compare ANIX vs Leading Stocks
See how ANIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANIX Anixa Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.